Schweitzer Engineering Laboratories

Newsroom

Nov 16, 2026

SEL Advances Development of Investigational Autism Screening Device, Launches Clinical Trial

Schweitzer Engineering Laboratories (SEL) is advancing development of an investigational medical device designed to support earlier identification of autism spectrum disorder (ASD). SEL has launched a clinical trial to evaluate the performance of the device in clinical settings as part of the regulatory and product development process.The clinical trial is being conducted in collaboration with the SEL Health Clinic, Palouse Pediatrics, and other pediatric and family medicine clinics in the Inland Northwest. The study is intended to collect data that may support future regulatory submissions and inform continued device development.ASD affects millions of individuals and families worldwide. Research has shown that earlier detection and intervention positively impact outcomes for children with autism, yet there are still challenges to receiving an early diagnosis to access these interventions in a timely manner. The investigational device is being developed to provide clinicians with objective information to assist in the screening process during routine healthcare.The clinical research study will evaluate the performance of the investigational hand-held autism screening device under approved ethical and regulatory oversight. Data collected during the trial will help researchers assess the capabilities of the device and inform future development efforts. Participation details will be communicated through separate, approved channels.The SEL device remains under investigation and has not been cleared for safety and effectiveness by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for commercial use.SEL announced its entry into medical device manufacturing in 2025, leveraging decades of experience in designing and producing highly reliable electronic technologies. The work SEL is doing on autism screening technology reflects its commitment to solving real problems through engineering, innovation and world-class manufacturing.“Every step forward in this work brings us closer to helping children and families access the support they need sooner,” said Edmund O. Schweitzer, III, SEL founder and chairman of the board. “Autism has touched my family and countless others. That is why this clinical trial is so important. By combining scientific research with our expertise in engineering and manufacturing at SEL, we hope to provide clinicians with a practical tool that supports earlier identification and, ultimately, better outcomes for children.”To learn more, visit selbioengineering.com/clinical-trial or click here to view the trial page at clinicaltrials.gov.
Back to Newsroom 
Featured Stories

Press Release

SEL Names New VP of Marketing and SEL University

Press Release

SEL Completes Purchase of New Post Falls Manufacturing Site

Corporate

SEL Invests More Than $500 Million to Expand U.S. Manufacturing Capacity

  • SEL Releases Two New Solutions for High-Density Serial-to-Ethernet Communications
  • SEL Expands Manufacturing Operations in West Lafayette

Contact Us

Corporate News

Kate Wilhite

+1.509.592.5109info@selinc.com
Follow